Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy-Reference-Cited by-同舟云学术

Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy

Published:2011-04-03 Issue:2 Volume:29 Page:627-632
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

An She-Juan,Huang Yi-Sheng,Chen Zhi-Hong,Su Jian,Yang Yan,Chen Jian-Guang,Yan Hong-Hong,Lin Qiu-Xiong,Yang Jin-Ji,Yang Xue-Ning,Zhou Qing,Zhang Xu-Chao,Wu Yi-Long

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-011-9924-x.pdf

Reference24 articles.

1. Wheatley-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol. 2008;3:1173–84.

2. Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355:2542–50.

3. Reck M, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21:1804–9.

4. Amir E, et al. Antivascular agents for non-small cell lung cancer: current status and future directions. Expert Opin Investig Drugs. 2009;18:1667–86.

5. Crinò L, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11:733–40.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients;Cancer Treatment and Research Communications;2020

2. Elevated GPC3 level promotes cell proliferation in liver cancer;Oncology Letters;2018-05-21

3. The Role of Angiogenesis in Non-small Cell Lung Cancer Tumor Behavior;Biochemical Basis and Therapeutic Implications of Angiogenesis;2017

4. JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances tantitumor function in a Fas/FasL signal-independent pathway;OncoTargets and Therapy;2016-07

5. Antitumor effect of recombinant human endostatin combined with cisplatin on rats with transplanted Lewis lung cancer;Asian Pacific Journal of Tropical Medicine;2015-08